49. ASCO 2023 - Metastatic Breast Cancer

Cancer is facing a seismic shift as precision oncology is becoming a reality, and adoption is skyrocketing as new anti-cancer agents are released. It appears that the days of blunt-force chemotherapy could be limited. Paul Ehrlich, the German Chemist, is credited with the term "chemotherapy", but more importantly, the concept of the magic bullet, "zauberkugel", which would allow selective targeting of pathogenic microbes without affecting other parts of the body. Leading the field of targeting cancer is metastatic breast cancer, as demonstrated by ASCO23. Oncology for the inquisitive Mind explores CDK4/6 sequencing, antibody-drug conjugates, and HER3 targeted therapy. Michael and Josh dissect the SONIA trial, sacituzumab govitecan use in the hormone receptor-positive space and partritumab deruxtecan, which could have pan-breast cancer utility.

Studies

SONIA: https://meetings.asco.org/abstracts-presentations/219701

TROPICS-02: https://meetings.asco.org/abstracts-presentations/219698

PARTRITUMAB DERUXTECAN: https://meetings.asco.org/abstracts-presentations/219699

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.